Alistair Ian Longshaw

This inventor holds 20 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 7 EPO patents. Top assignees: Respivert Limited, Topivert Pharma Limited, Albert Einstein College of Medicine. Active years: 2015-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alistair Ian Longshaw. Retrieved from https://idiyas.com/inventor/alistair-ian-longshaw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 1)

% Patents Active = 95.0

CIPO Patents = 3

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 128(Granted Patents)

Location History:

Thorndon, NZ (2016)
Nottingham, GB (2015 - 2023)

Company Filing History:

Topivert Pharma Limited

patents

2 out of 513

Albert Einstein College of Medicine

patents

4. 2 out of 53

Victoria Link Limited

patents

where one patent can have more than one assignee

Years Active: 2015-2023

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11634406 - Inhibitor of p38 MAP kinase (2023-04-25),

2. 11142515 - Pyrazolyl-ureas as kinase inhibitors (2021-10-12),

3. 10815217 - Inhibitor of p38 MAP kinase (2020-10-27),

4. 10813932 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2020-10-27),

5. 10738032 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors (2020-08-11),

6. 10294216 - Pyrazolyl ureas as kinase inhibitors (2019-05-21),

7. 10266519 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2019-04-23),

8. 10238658 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors (2019-03-26),

9. 10045980 - Inhibitor of p38 map kinase (2018-08-14),

10. 9993478 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors (2018-06-12),

11. 9957272 - 3-hydroxypyrrolidine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase (2018-05-01),

12. 9884845 - Pyrazolyl-ureas as kinase inhibitors (2018-02-06),

13. 9850231 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors (2017-12-26),

14. 9724347 - 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors (2017-08-08),

15. 9624196 - Inhibitor of p38 MAP kinase (2017-04-18),

Title: Alistair Ian Longshaw: Pioneering Inventor from Nottingham, GB

Introduction: Alistair Ian Longshaw is a distinguished inventor hailing from Nottingham, GB, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Alistair Ian Longshaw holds several patents in various technological domains, showcasing his versatility and ingenuity in creating novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Alistair Ian Longshaw has consistently pushed the boundaries of innovation, with his inventions revolutionizing industries and improving the lives of many around the world.

Collaborations: Alistair Ian Longshaw has collaborated with leading research institutions, universities, and companies to further develop and commercialize his inventions, demonstrating his commitment to bringing cutting-edge technologies to the market.

Conclusion: Alistair Ian Longshaw's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, inspiring the next generation of innovators to push the limits of what is possible.

Profile summary based on public USPTO records.